Novo Nordisk A/S' Shares Fall 15% After FDA's Tresiba Response-Reuters
Reuters reported that Novo Nordisk A/S' shares fell 15% after the United States FDA Tresiba response.
Latest Developments for Novo Nordisk A/S
- FSA reports Novo Nordisk A/S to police for violating disclosure obligations-Reuters
- Committee for Medicinal Products for Human Use Adopts Positive Opinion on NovoRapid PumpCart Developed in Partnership between Novo Nordisk A/S and Roche Diabetes Care
- Novo Nordisk A/S' NovoEight Passes Review by Committee on Drugs of Pharmaceutical Affairs in Japan
- Novo Nordisk A/S Gets FDA Approval for Medic Pen in United States-DJ
Latest Key Developments in Pharmaceuticals
- Plethora Solutions Holdings PLC announces CEO Appointment
- Merck & Co Inc announces launch of new business focused on weight management interventions in U.S.
- Coronado Biosciences Inc announces management changes
- Auxilium Pharmaceuticals Inc submits application to the FDA requesting approval of xiaflex for concurrent treatment of multiple palpable cords
- Share this
- Digg this